China's First Heart Failure Therapeutics Science Park Breaks Ground: Reliance Medical Initiates Construction of EVAHEART-Based Innovation Hub

On the morning of July 20, the groundbreaking ceremony for the Yongrenxin Medical Technology Park was held atLiangjiang New Area, ChongqingHeld with great ceremony.Member of the Party Working Committee and Deputy Director of the Administrative Committee of Liangjiang New AreaMr. Tao Pi, General Manager of Liangjiang Investment GroupMr. Yin Xiaohua、Ms. Xie Jing, General Manager of Liangjiang Investment Promotion Group; Ms. Yang Liqiong from Chongqing Modern Industry Research Institute; Ms. Zhang Ke, Deputy General Manager of Liangjiang Industrial Group; Mr. Li Chengyin, Deputy Secretary of the Party Committee and General Manager of Liangjiang Shuitou Investment Company; and Professor Wu Qingchen, Director of the Department of Cardiac Surgery at the First Affiliated Hospital of Chongqing Medical University, attended the event. Representatives from relevant departments of the Municipal Commission of Economy and Information Technology, the Municipal Medical Products Administration, Liangjiang New Area, and Shuitou New City, as well as company shareholders, partner institutions, and employee representatives, also participated in the ceremony.

Yongrenxin Medical Technology Park is China’s first industrial technology park dedicated to the treatment and management of heart failure. Leveraging “artificial hearts” as its cornerstone, the park focuses on high-end innovative medical devices, particularly for the critical care of severe heart failure. By integrating government, industry, academia, clinical practice, and research, it conducts R&D and manufacturing of innovative medical devices across areas including heart failure diagnosis, early prevention, intraoperative assistance, remote monitoring, ventricular support, and critical care diagnosis and treatment, thereby providing comprehensive, end-to-end solutions for healthcare institutions and patients with severe heart failure.

Yan Hua, CEO of Yongrenxin Medical, delivered the opening remarks. Yan stated that Yongrenxin Medical has always focused on the development of the heart failure and critical care diagnosis and treatment industry, striving to build a platform for multi-party exchanges and cooperation. Yongrenxin will create a “shared, diverse, green, and efficient” heart failure technology park to bring more advanced, higher-quality, and cost-effective medical products to more patients.

Zhang Benyan, Founder, Director, and General Manager of Yongrenxin Medical, reviewed the company’s journey over the past decade since its establishment. He expressed gratitude to the founding team, government leaders at all levels, shareholders, and partner hospitals for their consistent support. Mr. Zhang stated that the commencement of construction of the Yongrenxin Medical Science and Technology Park marks a strategic focus for Yongrenxin, building upon its existing industrial foundation. The company will further expand its product lines, enhance core competitiveness, cultivate specialized, refined, distinctive, and innovative capabilities (“Zhuan Jing Te Xin”), solidify its position as an industry benchmark, and establish itself as a world-class enterprise with international competitiveness.

In his address, Mr. Li Chengyin, Deputy Secretary of the Party Committee and General Manager of Liangjiang Shuitou Investment Company, stated that the Liangjiang New Area has designated the life and health industry as its third pillar industry for development and has formulated an action plan for this sector. As a shining gem in the life and health industry of Liangjiang Shuitou New City, Erenxin Medical has gathered top-tier medical technology resources and innovative capabilities. Seizing the opportunity presented by the groundbreaking ceremony of the Erenxin Medical Science and Technology Park, the Liangjiang New Area and Erenxin will further deepen their comprehensive cooperation. They aim to establish a high-quality innovation cycle integrating “technology, industry, and capital,” strengthen and supplement industrial chains, and accelerate the formation of an integrated industrial cluster encompassing the “innovation chain, industrial chain, and service chain,” thereby driving the high-quality development of the life and health industry in the New Area.

Following the completion of the groundbreaking ceremony, Mr. Fu Shan, Managing Partner, Co-CEO, and CEO of Greater China at VV Capital, as well as Chairman of EverRenxin Medical, delivered a vote of thanks to the attending guests. Chairman Fu stated that the construction of the EverRenxin Medical Science and Technology Park is a significant project undertaken in response to national calls and in alignment with market demands. EverRenxin Medical will focus on the field of heart failure, developing new therapies for the vast number of heart failure patients in China, and comprehensively advancing the development of China’s heart failure industry.

The construction of the Yongrenxin Medical Technology Park aligns with the development direction of China’s national strategic emerging industries. It is conducive to enhancing China’s independent innovation capabilities and international competitiveness in the field of heart failure, thereby promoting scientific research and technological innovation in this area. The technology park will gather outstanding heart failure experts, scholars, enterprises, and institutions from both domestic and international sources to jointly conduct basic research, clinical trials, product development, and translational applications in heart failure. It aims to foster academic exchanges and collaboration, cultivate talent reserves and professional teams in the field of heart failure, and establish an integrated development model involving government, industry, academia, healthcare, and research. This will enhance China’s international influence and competitiveness in cardiovascular diagnosis and treatment. Meanwhile, the Yongrenxin Medical Technology Park will also drive the development of the medical device industry in Chongqing and even the broader western region of China, facilitating regional economic transformation and upgrading, while increasing employment opportunities and tax revenue.

Heart failure is currently the only cardiovascular disease with a rising prevalence. Statistics show that there are 13 million heart failure patients in China, with approximately 700,000 patients suffering from end-stage severe heart failure requiring transplantation or artificial heart treatment each year. However, only about 600 donor heart transplantations are performed annually. The construction of the Everheart Medical Technology Park helps alleviate the supply-demand imbalance for heart failure treatment in China, thereby improving the treatment and survival rates of heart failure patients. As an innovative artificial heart product, Everheart’s EVAHEART can effectively extend patients’ life expectancy, serving as a lifeline for those awaiting transplantation or who are ineligible for it. Everheart’s continued investment in the field of heart failure through its Medical Technology Park will bring new technologies and therapies to more patients, increase the probability of early screening and treatment, reduce the overall incidence of heart failure, and lower national healthcare expenditures.

Yongrenxin Medical Device Co., Ltd. is a high-tech medical enterprise jointly invested by Chinese, Japanese, and American partners, specializing in device-based therapies for heart failure. Leveraging its domestically developed "Implantable Left Ventricular Assist System," Yongrenxin focuses on the field of high-end innovative medical devices, particularly for the treatment of severe heart failure. By integrating government, industry, academia, healthcare, and research efforts, the company engages in the R&D and manufacturing of innovative medical devices covering heart failure diagnosis, early prevention, intraoperative assistance, remote monitoring, ventricular assistance, and critical care management, thereby providing comprehensive solutions for healthcare institutions and patients with severe heart failure. The core product of Yongrenxin Medical is the implantable left ventricular assist device—"EVAHEART Yongrenxin" artificial heart. This product is currently the only artificial heart approved in China for long-term therapy and the only biomimetic artificial heart capable of generating pulsatile blood flow. In January 2020, the Yongrenxin Artificial Heart was awarded the "2019 Certificate of Major Advances in Chinese Medicine" by the Chinese Academy of Medical Sciences and was selected as one of the "Top Ten Scientific and Technological Achievements in China in 2019" by CCTV.com. It has been widely used in developed countries and regions such as Japan, Europe, and the United States, receiving official certification and consistent recognition from experts and scholars.